CCL22 and neoplasm: ESCC TAM-released CCL22 promoted tumor invasion and reduced patient survival via activation of the CCR4/DGKα/FAK complex in ESCC cells, revealing opportunities for targeting the tumor-promoting microenvironment to achieve anticancer effects [304].